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Human genome: UK to become world number 1 in DNA testing 
£300 million investment that will transform how diseases are diagnosed and 
treated announced by the Prime Minister today. 
 
https://www.gov.uk/government/news/human-genome-uk-to-become-world-number-1-in-dna-
testing 
 
 
On January 12, 2016, President Obama tasks Vice President Biden with 
leading a "Moonshot" to help end cancer as we know it. 
 
https://obamawhitehouse.archives.gov/node/352601 
 
 
Congress passed the 21st Century Cures Act in December 2016 authorizing 
$1.8 billion in funding for the Cancer Moonshot over 7 years. An initial $300 
million has been appropriated in fiscal year (FY) 2017 to fund Moonshot 
initiatives. 
 
Cancer Moonshot℠ was originally published by the National Cancer Institute. 
https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative 
 
 
The French government announced that it plans to invest €670 million 
($760.8 million) in a genomics and personalized medicine program meant to 
improve the diagnosis and prevention of disease in the country. 
 
https://www.genomeweb.com/clinical-translational/france-plans-invest-670m-genomics-
personalized-medicine 
 
 
The ballooning costs of healthcare act as a hungry tapeworm on the American 
economy. Our group does not come to this problem with answers. But we also 
do not accept it as inevitable. Rather, we share the belief that putting our 
collective resources behind the country’s best talent can, in time, check the 
rise in health costs while concurrently enhancing patient satisfaction and 
outcomes. 
 
Warren Buffett 
https://www.businesswire.com/news/home/20180130005676/en/Amazon-Berkshire-Hathaway-
JPMorgan-Chase-partner-U.S. 
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Deutsche Zusammenfassung / English Abstract / 
Grafische Zusammenfassung 
 
Deutsche Zusammenfassung 
 
Die Next-Generation-Sequenzierung (NGS) wurde zunächst als 
experimentelles Verfahren für explorative Studien und bei der Suche nach 
neuen wissenschaftlichen Erkenntnissen eingesetzt. In der Präzisionsmedizin 
gelten zusätzliche Rahmenbedingungen in Bezug auf konkrete klinische 
Fragestellungen, Wirtschaftlichkeit, Haftung und Reproduzierbarkeit. Im 
Rahmen der akkreditierten Diagnostik wird eine Dokumentation der 
Standardverfahren zur computerbasierten Validierung (in-silico-Validierung) 
von NGS-Ergebnissen in zunehmendem Maße gefordert.  
 
In dieser Dissertation beschreibe ich mögliche in-silico-Verfahren anhand 
meiner Veröffentlichungen zu der Backmapping-Methode sowie den 
Softwareprogrammen pibase und Vy-PER. Die Verfahren berücksichtigen 
potentielle Fehlerquellen aus der Biologie, dem Labor und der Bioinformatik.  
  
Meine Veröffentlichung A zu pibase befasst sich mit der Validierung von 
individuellen Einzelnukleotidsubstitutionen und einer systematischen 
Eliminierung von Fehlerquellen.  
 
Meine Veröffentlichung B zu Backmapping setzt sich mit potentiellen 
Artefakten auseinander, die auf biologischen Sequenzähnlichkeiten zwischen 
verschiedenen Bereichen innerhalb des menschlichen Genoms beruhen und 
daher bioinformatische Mehrdeutigkeiten bei der Ausrichtung der Sequenzen 
gegen ein Referenzgenom ergeben. Diese potentiellen Artefakte können mit 
Hilfe von alternativen Genomreferenzen und alternativen 
Ausrichtungsmethoden validiert werden. 
 
Meine Veröffentlichung C zu Vy-PER stellt eine verbesserte Methode vor, 
patientenindividuelle Virusgenompartikelintegrationen in das Patientengenom 
zu detektieren und Artefakte zu eliminieren.  
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English Abstract 
 
Next-Generation Sequencing (NGS) was initially used as an experimental 
method in exploratory research and in the search for novel scientific insights. In 
precision medicine additional critera apply, for example the testing method must 
answer specific clinical questions, while being subject to stringent standards of 
economy, liability and reproducibility. In accredited clinical NGS testing, 
laboratories must now increasingly document their standard procedures for 
computational validation (in silico validation) of NGS results.  
 
In this dissertation I describe possible in silico validation procedures based on 
my publications on the Backmapping method and on the pibase and  
Vy-PER software tools. These procedures take into account potential sources 
of errors from the biology itself, the lab methods, and bioinformatic methods.  
 
My pibase publication A deals with the validation of individual single 
nucleotide substitutions and the systematic elimination of error sources.  
 
My Backmapping publication B looks at potential artifacts that are based on 
biological sequence similarity between different regions of the human genome. 
These similarities may or may not lead to bioinformatic ambiguities when 
sequences are aligned to a reference genome. In consequence, potential 
artifacts may crop up which may only be exposed with the help of alternative 
genomic references and alternative alignment methods. 
 
My Vy-PER publication C presents an improved method to detect patient-
individual virus genome particle integrations into the patient’s genome and to 
eliminate artifacts.  
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Grafische Zusammenfassung 
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1. Introduction 
 
 
1.1 Aim of the study 
 
The aim of this study was to formulate reliable methods to discriminate 
between erroneous DNA variants from Next-Generation-Sequencing 
(NGS) and error-free DNA variants, so that NGS can be used not only 
for research but also for precision medicine. 
 
 
1.2 General Introduction 
 
 
Over the past decade next-generation sequencing (NGS) has helped to 
generate an incredible amount of knowledge. Today it is regarded as one 
of the most important standard methods in molecular biological research 
and is of fundamental importance for precision medicine. The IKMB has 
been sequencing human genomes of patients for ten years. Back then, 
the consumables required for sequencing a human genome had cost 
around 200,000 euros. The software for data evaluation and the methods 
of data interpretation had been in their infancy. Today, in 2018, the cost 
of consumables for genome sequencing has fallen to around 900 euros 
and data analysis is mature. In addition, the NGS technology and its clear 
advantages have been recognized by those responsible in the 
healthcare system. Since the first of July 2016, there exist billing codes 
in the German public health system (Abrechnungsziffern im Einheitlichen 
Bewertungsmaßstab, EBM), according to which the cost of NGS testing 
is regulated.  
 
 
Reimbursement 
for NGS testing 	
		 9 
The Genetic Testing Act (Gendiagnostikgesetz, GenDG) was passed in 
2009 and came into force on February 1, 2010. At the same time,  the 
Robert-Koch Institut founded the Gene Testing Commission 
(Gendiagnostik-Kommission). Its task is to draw up and regularly revise 
guidelines for the implementation of genetic testing 
(https://www.rki.de/DE/Content/Kommissionen/GendiagnostikKommissi
on/Richtlinien/Richtlinien_node.html). These guidelines mainly describe 
patient counselling and quality assurance for genetic tests. With regard 
to the analysis of the NGS data, there is however only the briefest hint in 
the Quality Assurance Guideline (Qualitätssicherungs-Richtlinie), with 
the following 20 words: "generally recognised state of the art in science 
and technology", which "therefore as a rule defines itself through 
generally accessible publications in specialised journals and textbooks" 
(“allgemein anerkannten Stand der Wissenschaft und Technik”, der “sich 
daher i. d. R. durch allgemein zugängliche Publikationen in 
Fachzeitschriften und Lehrwerken” “definiert”).  
 
Currently, in 2019, the Institute of Clinical Molecular Biology (IKMB) is 
introducing NGS testing for cardiomyopathies, pulmonary hypertension 
and immunodeficiencies at the University Hospital Schleswig-Holstein 
(UKSH) in cooperation with the Central Laboratory, the Center of 
Excellence for Inflammation Medicine and the Clinic for Internal Medicine 
III.  
 
Against this background, I would like to address my short dissertation not 
only to my referees but also to those scientists, technicians and clinicians 
who currently have to familiarize themselves with the "generally 
recognized state of the art of science and technology" in NGS. In the 
following, I will summarize the main findings from my publications and 
the therein presented Backmapping method as well as the software 
pibase and Vy-PER and I will explain them with regard to NGS data 
analysis for precision medicine. 
  
Generally 
recognised state 
of the art in 
science and 
technology 	
Genetic Testing 
Act (GenDG)  
and  
Guidelines by the 
Robert-Koch 
Institut 	
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2. Methodological considerations 
 
Genome-specific considerations for NGS analysis 
The human genome normally consists of 22 autosomal chromosome 
pairs and two sex chromosomes. Complete sequencing, i.e. complete 
coverage of the human genome, is not possible with NGS technology 
because the short sequences from an NGS instrument cannot be 
unambiguously mapped to all locations of a human reference genome. 
In addition, the reference genomes themselves are incomplete. We and 
others find that some of the human DNA sequences generated by an 
NGS instrument from a patient sample cannot be mapped using the 
current version of the human reference genome (hg38), but only using 
the BLAST database and website of the National Center for Biological 
Information (NCBI). Furthermore, there are difficult-to-sequence and 
difficult-to-map regions in the reference genome. These regions include 
repetitive Short Tandem Repeat (STR) and microsatellite sequences as 
well as complex sequences that may occur identically or similarly several 
times in the genome. The latter are referred to as sequence homologies 
and in certain cases as pseudogenes. In clinical testing,  pseudogenes 
have serious consequences, therefore I will dedicate a section to them 
in the discussion. 
 
 
Underlying NGS technology 
Today, sequencing-by-synthesis (SBS) technology dominates. It was 
developed at Cambridge University (Cambridge, UK), brought to market 
with the help of investors from 1998 to 2006 by Solexa Ltd (London, UK) 
and taken over in 2007 by Illumina Inc. (San Diego, USA) 
(https://www.illumina.com/science/technology/next-generation-
sequencing/illumina-sequencing-history.html).  
 
This NGS method is based on sequencing millions to trillions of short 
DNA fragments on a sequencing instrument and bioinformatically 
Gaps in the 
human reference 
genome 	
STRs and 
microsatellites 	
Sequence 
homologies, 
pseudogenes 	
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analyzing these sequences. In clinical testing, these sequences are 
usually aligned to human reference genome sequences. Put simply, if 
many sequences have the same nucleotide mismatch to the reference, 
then there is a plausible consensus that this mismatch is real (Fig. 1).  
 
 
Fig. 1: Sequence stack over reference genome sequence. Millions of short DNA 
fragments are sequenced in NGS instruments. In the case that a reference sequence for 
the organism is known, the seqeunces are then computationally aligned against the 
corresponding genomic reference sequences. The above example shows the genotype 
AG that was derived from mismatches in the shown sequences. True genotypes can 
usually be determined more reliably with increasing sequencing depth (coverage). 
(Figure: Illumina; permission granted) 
 
  
Consensus 
genotype AG 
from NGS 
sequences 
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As previously mentioned, the unique alignment of a short sequence 
against the human reference genome sequences is not always possible 
due to structural characteristics. Only about 95% of the genome 
reference can be uniquely mapped using sequences of 75 base pairs 
(bp) (1000 Genomes Project Consortium et al., 2010). Therefore, it is 
general practice to sequence both ends of a short DNA fragment (Fig. 
2). This sequence pair can be uniquely mapped to the reference genome 
in more cases than a single sequence. Using paired end sequencing, 
paired sequences of length 2 ´ 75 bp can be uniquely mapped to approx. 
97% of the reference genome, and 2 x 150 bp can be uniquely mapped 
to approx. 98% (1000 Genomes Project Consortium et al., 2010).  
 
 
Fig. 2: Paired end sequencing. Both ends of a DNA fragment are sequenced (here: 75 
nucleotides each) in order to improve the unique bioinformatic alignment of the 
sequences to the genomic reference sequence. 
 
In the first step of library construction, large DNA fragments are 
mechanically or enzymatically fragmented or alternatively transcribed as 
PCR amplicons from certain loci of the genome. For Illumina Paired end 
sequencing the required average DNA fragment length is usually about 
200-350 bp. Adapters are ligated to the DNA fragments (Fig. 3), which 
are complementary to primer molecules in the Illumina sequencing chip. 
The single strand molecules are thus bound to the primer molecules (Fig. 
4).  
 
75 nucleotides
75 nucleotides
paired end 
sequencing 	
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Fig. 3: Illumina sequencing library. Sequencing adapters with sequencing primer 
binding sites (Rd1 SP and Rd2 SP, respectively) are attached to each end of the double-
stranded DNA fragment. The adapters usually also contain a sample-specific DNA 
sequence (index), which allows many samples to be pipetted together and sequenced 
as a pool. The index allows (nearly) each sequence to be bioinformatically reassigned to 
the correct sample (demultiplexing). At the outer ends of the adapters there are 
complementary binding sites (P5 and P7) to primers in the Illumina sequencing chip 
("flowcell"), to which the binding takes place in the chip. (Figure: Illumina; permission 
granted)  
 
 
 
Fig. 4: Illumina sequencing chip showing bridge amplification and clustering. The 
sequencing libraries are denatured and bound at their adapters (P5 or P7) to the glass 
plate in the chip. Each library molecule is amplified with 10 bridge PCR cycles, resulting 
in a cluster of approximately 1000 library molecules. (Figure: Illumina; permission 
granted) 
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In the sequencing chip, bridge amplification is performed (Fig. 4) in order 
to amplify the optical sequencing signal of each single strand (Fig. 5) 
approximately one thousand times. 
 
 
Fig. 5: Illumina's SBS sequencing principle: Starting with the sequencing primer 
binding site (violet spheres), individual deoxyribonucleoside triphosphates (dNTPs) with 
attached fluorophore and reversible terminator are bound to the single strand cycle by 
cycle. The Fluorophores are laser-excited to emit a light signal, and photographed 
digitally. Then, the fluorophore and reversible terminator are cleaved off, after which the 
next cycle can begin. The translation of the light signal of each cluster (approx. 1000 
single strands) into a unique nucleotide is performed using "base-calling" software. 
(Figure: Illumina; permission granted) 
 
 
Errors may occur when incorporating individual deoxyribonucleoside 
triphosphates (dNTPs) during the sequencing process (Fig. 5). If a dNTP 
is not incorporated and the subsequent light signals thus shift, this is 
known as "phasing" (Fig. 6), conversely (if several dNTPs are 
incorporated instead of one dNTP) as "prephasing" (Kircher, Stenzel and 
Kelso, 2009; Ledergerber and Dessimoz, 2011).  
 
Signal noise due 
to phasing and 
prephasing: from 
adjacent bases 	
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In the data analysis, phasing or prephasing has the effect that a putative 
variant is detected which, on closer examination, consists of one of the 
two neighboring nucleotides in the reference sequence and usually has 
a much lower allele frequency than a true consensus genotype. 
 
 
Fig. 6: Phasing and prephasing - dNTP incorporation errors: Left: Phasing is the 
failure to incorporate a dNTP, probably because the blocker of the previously 
incorporated dNTP was not removed correctly. Middle: Single strands without 
incorporation errors. Right: Prephasing is the incorporation of two dNTPs, probably due 
to a blocker defect. (Sources: Image courtesy of the Broad Institute, 
https://www.broadinstitute.org/files/shared/illuminavids/dataSlides.pdf, https://www. 
ecseq.com/support/ngs/why-does-the-sequence-quality-decrease-over-the-read-in-
illumina ) 
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Standard sequence data format and quality or Phred score 
 
The standard format for NGS sequences is the compressed FASTQ 
format (FASTQ.gzip), an extended FASTA format: In addition to the 
base information of the FASTA format, it also contains a quality value 
for each base, which is based on that of the program phred (Ewing et 
al., 1998). The PHRED score, also called Base Quality, is defined 
as follows: 
Error probability := 10 - (PHRED/10) 
e.g. error probability = 10 -(20/10) = 10 -2 = 1% for PHRED = 20 
 
The quality of a sequence alignment against a reference sequence is 
described by a value that is inspired by the PHRED score and referred 
to as Mapping Quality. Both the Base Quality and the Mapping 
Quality serve only as indicative estimates and not as absolutely 
reliable quality values. 
 
  
Quality  
or  
PHRED 	
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STR noise - technical or biological blurring ? 
 
As previously mentioned, STRs and homopolymeric sequences (Fig. 7) 
are among the regions of the genome that are difficult to accurately 
sequence and map to. This has both a biological reason and a technical 
reason. STRs mutate 100,000 to 1,000,000 times faster than single 
nucleotide variants (Forster et al., 2015). In some individuals, some STR 
regions may become genomically unstable in some cells, i.e. they 
become longer or shorter in the course of life and can initiate diseases 
such as ataxias and Huntington's disease; coding region trinucleotide 
STRs become instable when 29-39 repeats are reached (McMurray, 
2010). On the other hand, the technical artifact of "PCR stutter" is known 
from forensic STR analysis. Most bioinformatic methods cannot 
distinguish PCR stutter from biological length changes and therefore 
often report false-positive variants. 
 
A validated STR analysis method should therefore be used in clinical 
testing, e.g. MSI sensor for somatic tumor/normal analysis (Niu et al., 
2014). If no validated method for STR analysis is used, the NGS results 
in STR regions should be ignored. This includes homopolymeric runs, 
i.e. sequence regions in which the same nucleotide occurs several times 
in succession. Of clinical importance, certain homopolymeric regions are 
used in human genetics and pathology as microsatellite markers for 
Lynch Syndrome and for microsatellite instable tumors (Umar et al., 
2004). For mitochondrial DNA it was shown that homopolymers with a 
length of 8 bp or longer can be highly mutable (Forster et al., 2010). In 
clinical testing software such as GenSearchNGS (PhenoSystems S.A., 
Blonay, Switzerland), the filtering of variants in homopolymeric regions is 
a standard option. 
Be aware of STR 
and 
homopolymer 
regions. 	
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3. Method for the technical validation of single 
nucleotide variants - pibase 
 
Publication A (see page 60): 
 
Forster M, Forster P, Elsharawy A, Hemmrich G, Kreck B, Wittig M, 
Thomsen I, Stade B, Barann M, Ellinghaus D, Petersen BS, May S, 
Melum E, Schilhabel MB, Keller A, Schreiber S, Rosenstiel P,  
Franke A.  
From next-generation sequencing alignments to accurate comparison 
and validation of single-nucleotide variants: the pibase software.  
Nucleic Acids Res. 2013 Jan 7;41(1):e16 
 
Most genetic variant detection programs were not developed for clinical 
testing of individual patients, but for studying population genetics in 
diploid and healthy individuals. Depending on the software and software 
settings, a number of real alignment errors and real sequencing errors 
as well as biologically real genetic variants may be filtered out. An 
approach to determine real genetic variants more confidently is therefore 
to call variants using two or more software tools with default settings, and 
then to perform the intersection of all mutation lists. On the other hand, 
sensitivity can be improved by forming the union of all mutation lists 
(Wang et al., 2013).  
 
The functionality of the pibase software is based on a similar idea. The 
software internally uses ten different genotyping methods, which differ in 
increasingly stringent quality filters. pibase takes up the previously 
investigated idea of mathematical convergence of genotyping stability 
with sequencing depth (Melum et al., 2010). Thus pibase not only 
provides a "consensus genotype" but also a statement about the 
variability or stability of this genotype.  
Consensus of 
ten separate, 
increasingly 
stringent 
methods for 
genotyping 	
		 20 
pibase uses the following checks to determine whether a genotype is 
stable: 
• Does the genotype change between sequence variants with low 
base quality and sequence variants with high base quality? 
• Does the genotype change between deduplicated sequences 
(unique start points after (Melum et al., 2010)) and non-duplicated 
sequences? 
• Does the genotype change between short sequences and long 
sequences? 
• Does the genotype change between sequences with one 
mismatch and sequences with several or many mismatches? 
• Does the genotype change between sequences with poor 
mapping quality and sequence variants with high mapping 
quality? 
 
Furthermore, pibase documents whether the genotype is sequenced 
on the forward and backward strands (Fig. 8, independent supportive 
observations) or only on one strand. In addition, pibase checks and 
reports whether the genotype lies in a hypervariable (Fig. 9) or 
homologous region (Fig. 10) of the genome reference. Finally, pibase 
tests the flanking bases of the reference sequence for homopolymers 
and dinucleotide STRs.  
 
As a result, pibase provides a comprehensive summary table of the 
above results (Fig. 11) as a valuation aid for real variants or technical 
artifacts. This table can be filtered automatically to separate stable 
genotypes from possibly false positive signals. The table is intended for 
automatic technical validation within a clinical bioinformatics solution as 
well as for manual technical validation in order to save extensive manual 
work in the viewer. Input file formats for pibase may be a text file of 
genomic positions or a standard VCF file (variant call format).  
 
Detailed 
technical report, 
see 
 Fig. 11 	
Double 
strandedness, 
hypervariability, 
homology 	
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To validate potential somatic variants in tumor DNA versus normal DNA, 
pibase does not compare genotypes but the underlying original 
alignment files, using an eight-field Fisher's exact test and constraints. 
This test was also used in the above-mentioned publication A for the 
labour-saving comparison of germline variants of identical twins. The 
Fisher's exact test is now a generally used standard method for 
comparing tumor/normal NGS data pairs (Xu, 2018). 
 
pibase is suitable for the detailed examination of given (!) positions in a 
genome and thus for the decision whether detected variants are real 
variants or false positive signals. pibase is not suitable for the actual 
detection of variants. To scan for putative variants, it is best to use 
several variant detection programs with sensitive settings and pool their 
results.  pibase can then be used for the technical validation of putative 
single nucleotide variants. A detailed description of pibase can be 
found on the homepage 
http://www.ikmb.uni-kiel.de/pibase . 
  
Fisher's exact 
test (8 fields) for 
comparing 
alignments 	
pibase 
homepage 	
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Key results: 
 
On the basis of publicly available 1000 Genomes alignment data (BAM 
files) with an average 30-fold sequencing depth, pibase achieved a 
genotyping specificity of 99.97-100.00%.  
 
By analyzing two monozygotic but phenotypically discordant pairs of 
twins, co-author Britt-Sabina Petersen and I were able to show that 
pibase significantly reduces manual work compared to conventional 
analyses. Using the p-value of the Fisher's exact test, we were able to 
reduce the de novo mutation candidate list between twins from hundreds 
of mutation candidates to 5 and 15, respectively, by filtering with p < 0.01. 
Interestingly, only zero to two de novo mutations occur in the exome 
between parent and child (1000 Genomes Project Consortium et al., 
2010; Girard et al., 2011). Genetic differences between monozygotic 
twins are rarely found within the exome regions (Petersen et al., 2014). 
 
These convincing results indicate that the pibase methods would be 
useful if integrated into clinical diagnostic solutions. 
Specificity  
99.97-100.00 
at 30X 	
10-fold  
less manual work 
when comparing 
identical twins 	
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4. Method for technical validation of alignments of 
sequences containing single nucleotide variants - 
Backmapping 
 
Publication B (see page 61): 
 
Elsharawy A*, Forster M*, Schracke N, Keller A, Thomsen I, Petersen 
BS, Stade B, Stähler P, Schreiber S, Rosenstiel P, Franke A.  
Improving mapping and SNP-calling performance in multiplexed 
targeted next-generation sequencing.  
BMC genomics. 2012 Aug 22;13:417. 
* joint first author 
 
In the early days of the NGS, there were no fast software tools for aligning 
sequences to a reference sequence. Therefore, researchers studied 
whether aligning short NGS sequences to a small reference sequence 
yielded sufficiently accurate results, in analogy to aligning long Sanger 
sequences to short references. This approach would have accelerated 
the long computing times. However, in some cases this approach 
generates artifacts that are reported as variants by the bioinformatics 
software.  
 
In publication B we presented the Backmapping method to detect and 
undo these artifacts. In the first step we used a very small reference 
sequence (i.e. the exome reference sequence) instead of the complete 
human genome reference sequence to identify potential variants. The 
resulting potential artifacts (Fig. 12A) were identified in a postprocessing 
operation as follows: First, all NGS sequences with the respective 
mismatch to the reference sequence were extracted from the alignment 
file. Then these sequences were aligned to the whole human genome 
small reference 
sequence 	
Test "mutated" 
sequences 
against whole 
genome	
	 28 
and finally the genotypes were tested with pibase at the genomic 
coordinates of the previously identified variants. Artifacts were classified 
as those variants that could no longer be detected after alignment against 
the complete human genome (Fig. 12B). Our automated backmapping 
had thus identified and removed potential artifacts.  
 
In today's interactive sequence viewers such as IGV, Seqpilot (JSI 
medical systems GmbH) and GenSearchNGS (Phenosystems S.A.), the 
user can interactively select and copy a sequence (Fig. 13). For manual 
validation of a variant, this sequence can be aligned to the human 
genome via the BLAT website (https://genome.ucsc.edu/cgi-bin/hgBlat) 
(Fig. 14). The sequence can be aligned to known human and non-human 
sequences using nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TY
PE=BlastSearch&LINK_LOC=blasthome) (Fig. 15). In the special cases 
of sequences with insertions or deletions or similarities to multiple 
regions in the reference genome, this validation is good practice 
(Fig. 16). For validating single nucleotide substitutions in sequences 
without insertions or deletions, pibase is usually sufficient. 
 
Publication B also presents the results of a subproject within the EU 
project READNA as well as the experiences with faulty and slow 
bioinformatics tools. A short time later, the variant detection programs 
SAMtools (Li et al., 2009) and GATK (McKenna et al., 2010) were 
revised to enable more time-saving exome and panel analysis. However, 
the problem of false-positive variant detection is still relevant today.  
 
 
 
automated 
backmapping	
today: manual 
backmapping 
with IGV, BLAT 
and BLAST	
faster software 
for exomes	
	 29 
Today, every single variant has to be validated before it can be included 
in a clinical report. Validation of single nucleotide substitutions can 
nowadays be assisted by pibase. Manual checks remain necessary for 
insertions and deletions. 
 
In summary, publication B contains three significant messages that 
have a practical value for the clinical application of NGS to this day:  
 
(1) We recommended the backmapping method for validating 
potential false positive variants. In interactive form, I recommend 
Backmapping with today's alignment viewer programs: extract 
an individual sequence containing the detected variant and check 
its alignment with BLAST and BLAT, as well as checking for 
possible contamination with BLAST. 
 
(2) In READNA, we demonstrated for the first time that targeted 
enrichment of genomic target regions using hybridization probes 
works not only for DNA fragments - as had been standard 
protocol - but also for NGS libraries with sequencing adapters as 
well as for pooled ready-to-use libraries with sequencing adapters 
and sample-specific molecular barcodes/indexes (Fig. 3). The 
latter two methods are standard protocol today. 
 
(3) In READNA, we recommended technical replicates. Today, many 
laboratory methods are more mature than in the past. For DNA 
from fresh EDTA blood or fresh frozen tissue, technical replicates 
are usually no longer necessary.  In contrast, I recommend 
technical replicates for potentially modified DNA or RNA - e.g. 
DNA from FFPE tissue (Do and Dobrovic, 2012) - even today.  
 
Backmapping 
as QC 	
Targeted 
enrichment of 
NGS libraries 	
Technical 
replicates 	
Clinical testing: 
Validate each 
variant 	
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5. Method for the detection of virus integrations into 
the human genome - Vy-PER 
 
Publication C (see page 62): 
 
Forster M, Szymczak S, Ellinghaus D, Hemmrich G, Rühlemann M, 
Kraemer L, Mucha S, Wienbrandt L, Stanulla M; UFO Sequencing 
Consortium within I-BFM Study Group, Franke A.  
Vy-PER: eliminating false positive detection of virus integration events 
in next generation sequencing data.  
Sci Rep. 2015 Jul 13;5:11534. 
 
 
In Chapter 4 I noted that the ubiquitously used BWA software from 
Richard Durbin and Heng Li can occasionally produce erroneous results 
(Fig. 16). These errors can also lead to false-positive conclusions about 
pathogens, such as viruses, bacteria and protozoa. At the 2012 annual 
conference of the Arbeitsgemeinschaft für GenDiagnostik e.V. Zemin 
Zhang reported that his group was able to detect hepatitis B virus 
integrations into the human genome in some cases of liver cancer, using 
NGS.  
 
Building on Zemin Zhang's method (i.e. mapping sequences to the 
human genome and using BLAST to align the unmapped sequences to 
virus databases), I introduced step-by-step improvements with the aim 
of eliminating the large number of false-positive virus sequences 
(Fig. 17).  
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Fig. 17: Paired-end sequencing enables the detection of patient-individual virus 
integrations into the human genome. The image is reproduced from my publication 
and summarizes the algorithm. 
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Vy-PER searches for human virus chimeras in paired end sequence 
pairs. The user may choose whether Vy-PER should consider single 
chimeric pairs (highest sensitivity) or a specific minimal number of 
chimeric pairs in the same locus (higher specificity). Vy-PER filters non-
specific sequences that consist only of STR sequences or homopolymer 
sequences in the "virus" subsequence. Vy-PER tests the more complex 
virus sequences for a possible human origin by mapping them to the 
human genome using the exact Smith-Waterman algorithm. Using Vy-
PER on more than a hundred patients’ sequences has shown that even 
complex-looking “virus” sequences can be identical to sequences in the 
human genome. 
  
Overcoming my initial reservations concerning the results from Zhang's 
group, Vy-PER reproduced that HBV integrations can be detected in 
public liver cancer genome sequence data (Sung et al., 2012) and 
transcriptome sequence data (Chen et al., 2013): Figure 18 shows the 
integration loci of hepatitis B virus fragments into a patient genome 
determined by Vy-PER. The patient's sequence data originate from  
transcriptome sequencing by Chen and colleagues. Figure 19 shows an 
analysis of the same data set with the highest sensitivity: Allowing 
individual human-virus chimeras, Vy-PER also detected the PhiX spike-
in, which is necessary for the Illumina sequencing method. These PhiX 
control libraries are normally spiked into the sequencing libraries at a 
ratio of 1:99 in order to better eliminate the phasing errors (see chapter 
1 "Introduction"). We interpret the chimeric PhiX sequences as being 
PhiX libraries ligated end-to-end with human libraries. Similarly, I 
occasionally find chimeric sequences where human libraries appear to 
be ligated end-to-end with libraries from non-integrating pathogens. I 
speculate that the  known PhiX spike-in may potentially allow the 
estimation of the non-integrated pathogen load. 
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Fig. 18: Vy-PER high specificity results ideogram. Plot from my publication with HBV 
integration loci on chromosomes 4, 11 and 16. Only loci with 10 or more chimeric 
sequence pairs within a genomic seuqence window of 1000 bp were considered. These 
loci were concordant with the loci published by Chen et al. 
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Fig. 19: Vy-PER high sensitivity results ideogram. Plot from my publication. The HBV 
integration loci on chromosomes 4, 11 and 16 are concordant to the loci published by 
Chen et al. In addition, I detected further potential integration loci when chimeric 
sequence pair singletons were considered. Compared to Fig. 16, these further potential 
HBV integration loci into the patient genome as well as PhiX chimeric sequence pairs 
(which are not integrated into the patient genome) can be seen. 
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6. Discussion 
 
Unvalidated raw NGS results are currently not suitable for clinical use. 
This applies to results generated by popular research bioinformatics 
software as well as data generated by commercial clinical testing 
software. Therefore, standard practice is to validate the raw data using 
independent methods, mostly by visually inspecting the sequence 
alignments in visualization software and, in the case of individual 
uncertainties, often also by Sanger sequencing. These validation 
processes are increasingly being formalized with the aim of 
standardized, reproducible processes. During the accreditation 
inspection at IKMB in January 2018 by DAkkS auditor Prof. Dieter 
Lohmann, our clinical testing lab was for the first time requested that our 
standard procedure for identifying artifacts be recorded in writing. This 
request is now answered with my publicly available dissertation, which I 
would like to encourage other clinical testing labs to re-use. 
 
The pibase scripts enable the automated validation of single nucleotide 
variants, except for the case of sequences with indels. I use pibase 
regularly in research to filter technical artifacts and unclear variants from 
raw variant lists, e.g. in (Zeissig et al. 2014; Fischer et al. 2015). 
According to Google Scholar (scholar.google.com) pibase is 
currently cited by 22 publications. 
 
I have used Vy-PER for virus analysis in the published leukaemia cases 
and also for exploratory analysis of other patient sequences. Occasional 
feedback shows that the topic of false-positive virus detection continues 
to be one of the research interests of bioinformaticians on the American, 
Asian, Australian and European continents in 2018 and 2019. According 
to Google Scholar,  
Vy-PER is currently cited by 16 publications.  
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The Backmapping method from our BMC genomics publication is not 
used in our current standard bioinformatics pipelines. Nowadays, 
computing time can be saved by specifying the target regions of interest 
using a BED file. However, we nowadays use Backmapping "manually" 
in routine clinical testing when we use the independent - and often more 
accurate, but slow - mapping software BLAT and BLAST for the technical 
validation of suspicious sequence alignments to the human genome 
reference. Figure 20 shows an example of such an artifact. The 
sequences probably originate from the patient's pseudogene locus 
TYRO3P, but were assigned to the locus of the similar gene TYRO3 
(Figure 21). This shows how important it is to perform Backmapping 
validation for suspicious variant-calls, especially when exome 
sequencing or unfamiliar gene sets are used.  
According to Google Scholar, the Backmapping paper is currently 
cited by 10 publications. 
 
It should always be borne in mind that NGS databases and analysis 
software seldom conform to good craftsmanship. Outstanding 
exceptions are IGV (Robinson et al., 2011; Thorvaldsdóttir, Robinson 
and Mesirov, 2013) and HLAssign (Wittig et al., 2015). Three important 
problems should be remembered: 
 
1. As a rule, bioinformatics software has too many "dependencies" 
on other software or databases, which means that it is practically 
unusable from the start or becomes unusable later when an 
updated version is released. The term for this problem is 
"dependency hell". When deciding on a bioinformatics solution, 
particular attention should be paid to this problem. 
 
2. Annotations can be misleading, even in some of the commercial 
clincial testing software versions that I have tested so far, as well 
as in the leading open clinical variant database ClinVar. 
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Annotations must therefore be validated in routine clinical testing. 
The database issues are known (Lek et al., 2016) and are 
currently being addressed (keyword search "theatlantic Heidi 
Rehm PTPN11 Noonan" or https://bit.ly/2mFgxeJ). Today, it is 
standard practice in clinical testing that variants with population 
allele frequencies in cohorts of healthy control subjects greater 
than 1% must be classified as benign. The most important publicly 
accessible healthy controls are GnomAD 
(http://gnomad.broadinstitute.org/about) and two cohorts of 
healthy old control persons: the Welderly cohort (Erikson et al., 
2016) and the cancer-free FLOSSIES - Fabulous Ladies Over 
Seventy (https://whi.color.com).  
 
3. Quality assurance of databases or software is passed on to the 
users when "agile software development" is performed, even in 
the case of some software from commercial providers (Figure 
22). Therefore, in accredited clinical testing labs a careful 
validation of each new software version becomes necessary, if 
solutions from agile software developers are used.  
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Significant new findings 
 
 
Fig. 23: Comparison of the previous state of science and knowledge with 
significant new findings from my works 
 
Figure 23 summarizes significant new findings that have been gained 
through my contributions presented here. Some of my findings build on 
previous work that others carried out at IKMB (Melum et al., 2010). 
Melum and colleagues used the concept of unique start points to 
eliminate potential sequence duplicates; by randomly subsampling 
sequences they observed that NGS variant-calling became increasingly 
uncertain at sequencing depths of less than 30X.  
 
I built on their work, exploring additional criteria of my own choice 
(comparison between duplicated and deduplicated sequences, 
comparison between short and long sequences, comparison between 
sequences with many or few mismatches to the reference genome, 
comparison between sequences with high or low alignment quality, 
comparison between variants with high or low Phred score, use of a 
Significant new findings of relevance to 
science and clinical genetic testing
Highly specific genotype convergence when stepwise 
filtering systemic errors: 
PCR-duplicates, sampling/sequencing depth, device 
errors, alignment, reference sequence.
pibase 99.99-100% specific, typing HapMap SNPs in 
30X whole genome sequences.
Comparisons (tumor-normal or twin pair): 
Fisher’s exact test more specific than genotype calls.
Formalisation of NGS variant calling and
NGS quality control / technical validation.
Mapping artefacts caused by target region alignment.
QC for artefacts, contaminations by backmapping 
to whole genome references, to other/all organisms.
Previous state of
science and knowledge
Consensus variant calling 
from sum of NGS sequences.
Coverage depth > 30X else instable variant-calls.  
Hypothesis: Improved NGS accuracy with GATK 
(statistical variant caller).
NGS unreliable, Sanger-Sequencing reliable.
Hypothesis: sequence alignment to target regions 
of interest, in analogy to Sanger sequencing.
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strand bias criterion as well as the reference sequence context). When I 
submitted my first pibase manuscript version, these criteria were still 
quite novel considerations and they generated resistance. Today, it has 
become common practice to use some of the criteria described in the 
pibase publication.  
 
The use of Fisher's exact test to improve tumor/normal comparisons and 
intra-twin comparisons was described in the pibase manuscript and 
proposed by co-author Peter Forster. We were the first to publish the use 
of the Fisher's exact test for NGS and it is now used in many analysis 
programs for tumor NGS data. The idea of the Backmapping method 
is derived from co-author Andreas Keller’s variant quality control 
procedure: He used BLAST for mapping to the human reference his test 
sequences that consisted of each putative variant plus 50 bases of 
upstream and downstream padding from the reference sequence. 
 
My dissertation thus clarifies the specificity of NGS variant-calling and 
provides tools or procedures how artifacts can be detected and removed. 
This expert guidance is solidly founded on nearly ten years of intensive 
study of NGS data. 
  
	 48 
7. Outlook 
 
The primary aim of my future work is to develop precision medicine 
approaches and translate these into general patient care through 
interdisciplinary cooperations with natural scientists and clinicians.  
 
Several ongoing pilot projects have already generated human sample 
collections and noteworthy results that merit potential scientific 
publication, initiation of clinical trials, and grant applications for third-party 
funding to finance the required human and material resources.  
 
The currently ongoing projects are based at several clinics that collect 
tissue and/or blood of cancer patients. Their goals are to understand and 
ultimately use patient-specific molecular biomarkers in longitudinal 
follow-ups to help guide therapeutic interventions. These promising 
strategies are already being implemented by the large US cancer 
centers, especially for rich or privately insured patients. However, my 
wish is that normal patients with just the basic German public health 
insurance may also benefit from these precision medicine strategies at 
economically acceptable costs. 
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1. Safety of therapeutical virus integrations1,2 
1) Baum et al. Mol. Ther. 2006. PMID: 16632409 
2) Bertino et al. Int. J. Cancer 2013. PMID: 23335100 
Herpes beware:  
eliminating false positive virus detections in NGS data  
resulting from alignment biases 
 
Michael Forster*, Silke Szymczak*, David Ellinghaus, Georg Hemmrich,  
Lars Kraemer, Sören Mucha, Lars Wienbrandt,  
Martin Stanulla for the UFO Sequencing Consortium within the ALL-BFM Study Group 
 and Andre Franke  
  * these two authors share first authorship, manuscript in revision  
Motivations: therapeutical safety and etiological research 
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False positive human/virus chimeras 
reduced more than 1000-fold 
 
Singleton human/virus chimeras 
easily detectable 
Results 
Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Germany 
m.forster@ikmb.uni-kiel.de, http://www.ikmb.uni-kiel.de 
2. Virus integrations and disease associations3,4,5 
Zhang Nat. Genet. 2012 
Methods: classical and improved approaches (Vy-PER**) 
human reference hg19 
known virus references 
human paired-end reads 
Map paired-ends to human genome. 
Map unmapped reads to virus database (NCBI, etc.). 
Filter low-complexity reads. 
 
Problem: >1500 false positive chimeras per HiSeq lane 
Classical Improved (VirusSeq6) Further improved (Vy-PER) 
Problem fix:  
Cluster virus integration sites 
 
 
New problem:  
Loss of sensitivity if 
1) only fraction of cells affected 
2) integration locus heterogeneity 
Multi-step elimination of false positives without impairing 
sensitivity. 
Use of exact alignments (Smith-Waterman). 
Speed-up of Smith-Waterman: FPGA (3000× single core speed) 
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Vy-PER 
virus-positive 
example: 
 
HBV virus integration 
 
RNA-Seq  
 
FASTQ files from  
VirusSeq web page6 
 
 
 
This plot only shows  
integrations supported  
by 10 or more chimeras 
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Vy-PER 
virus-negative  
example: 
No virus integration 
 
Whole genome 
80× coverage 
 
This plot shows integration 
sites down to single chimeras 
 
12,000 false positive chimeras 
were reduced to 3: 
Caviid herpes, Cercopithecine, 
Pseudomonas 
 
PhiX + M13: Illumina  
control library spike-in 
**acronym for Virus integration detection by Paired-End Reads 
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6) Chen et al. Bioinformatics. 2013. PMID: 23162058 
	 66 
X. HiTSeq 2014 Poster Award for Vy-PER  
 
 
